Enzo Biochem, Inc. (NYSE:ENZ) Files An 8-K Other Events
Item 8.01.
On February 19, 2020, Enzo Biochem, Inc., (“Enzo”) issued a press release.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
(d) Exhibits.
| 99.1 | Press Release, dated February 19, 2020. |
ENZO BIOCHEM INC Exhibit
EX-99.1 2 c95299_ex99-1.htm Exhibit 99.1 For Immediate Release Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1-I in a Model of Lupus Drug Candidate SK1-I Shown to Markedly Decrease Lupus-Associated Immune Criteria and Kidney Inflammation in Preclinical Study Study is Further Confirmation of Enzo Biochem’s Proprietary Compound’s Potential for Treatment of this and other Autoimmune Diseases NEW YORK,…
To view the full exhibit click here
About Enzo Biochem, Inc. (NYSE:ENZ)
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.
